Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
Files
Publication date
2019-05-01
Authors
Tonk, EHJ (Erwin)
van Lindert, Anne S.R.
Verhoeff, Joost J C
Suijkerbuijk, Karijn P M
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during durvalumab administration for locally advanced NSCLC, causing persistent symptomatology and steroid treatment to date. To our knowledge, acute-onset pneumonitis during infusion of a PD-L1 inhibitor has not been described previously. This case illustrates that ICI-induced pneumonitis can occur anytime during treatment, especially after chemoradiation.
Keywords
Adjuvant, Anti-PD-L1, Immune checkpoint inhibitor, NSCLC, Pneumonitis, Oncology, Case Reports
Citation
Tonk, E H J, van Lindert, A S R, Verhoeff, J J C & Suijkerbuijk, K P M 2019, 'Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab', Case Reports in Oncology, vol. 12, no. 2, pp. 621-624. https://doi.org/10.1159/000502202